Founded in 2017 by two respiratory clinicians following 11 yrs of NHS-led and funded research.

Our Mission

To improve the lives of people with COPD through life-changing digital predictive solutions that prevent 50% of COPD-related hospitalisations and re-admissions.

Our Vision

To be a global leader in personalised prediction and prevention of COPD exacerbations: making a difference to the lives of people with COPD

Our Evidence

Clinical studies demonstrated 97% reduction in hospital admissions using predict to prevent intervention as part of proactive self-management.

Our Partners

Patients, clinicians, hospitals, policy makers and Industry provide a robust eco-system to ensure our products remain cutting edge and competitive.

“COPD is third leading cause of death worldwide, exceeded only by heart disease and stroke.”

“COPD is  second major cause of unplanned hospital admissions accounting for 12% of total admissions.”


NEPeSMO offers a smart CE-marked digital monitoring solution with AI-analytics for the prediction of COPD exacerbations and prevention of hospitalisations. COPDPredicthas been co-designed with patients and is bespoke to patients living with COPD. Proprietary prediction algorithms are constructed from time-series data on symptoms, lung function and biomarkers in blood/saliva supplied by patients using a bespoke App that connects wirelessly to monitoring devices. A dedicated web-based Clinician Early Warning System provides the healthcare team with real-time information on their patients and alerts on impending exacerbations, allowing prompt intervention.

Aspects of COPDPredict™ are patent-protected: US 8,812,249 B2; Canada 2,766,699 C and EP 2446386 B1.

What Our Patients say

Direct quotes from COPD patients using our Predict to Prevent intervention.

Executive Chairman & CEO
Trevor Phillips

30 yrs+ experience in the Pharma Industry with strong business leadership and corporate development roles in public & private companies in UK and USA. Previous positions: CEO Open Orphan PLC, Executive Chairman hVIVO PLC; CEO & COO Vectura Group PLC, CEO & COO Critical Therapeutics Inc.

Co-Founder & Chief Operating Officer
Monica Spiteri

Respiratory physician with 30 yrs+ experience working in the NHS. Named inventor on patents. Held executive leadership roles in European Respiratory and British Thoracic Societies. External advisor, EC Horizon 2020 Personalising Healthcare and various pharmaceutical companies.

Co-Founder & Chief Medical Officer
Neil Patel

Respiratory physician, named inventor on patents. 10 years’ experience in managing project finances/records and research background in saliva diagnostics and prediction algorithm construction.

Chief Technical Officer
Atif Syed

Experienced founder of UK start-up SW company. 15 years+ experience in innovative software solutions and specialist in AI and IoT driven applications in healthcare.

Non-Executive Board Director and Commercial Advisor
Roger Heerman

Extensive US & international commercialisation experience in a number of senior roles, including EVP of Commercial and Business Development at Vectura Group PLC, VP Sales and Marketing at Critical Therapeutics, Inc. and VP director of client service at McK Healthcare.

Latest News

RemoteCovid Launched

13 April 2020 – We are thrilled that the NEPeSMO team has successfully delivered a digital web- based solution, RemoteCovid, within 4 weeks. This is free for use to all people living in the UK to help them self-monitor and communicate progress reports with their healthcare team or others as and when required. (www.remotecovid.co.uk)

Contact Us For Collaborations, Questions Or To Say Hi

For all enquires related to sales, demos, investment opportunities etc , please contact us using this form.

Office Address

76 King Street,

Manchester, M2 4NH,

United Kingdom,

Registered Address

TC Group, Level 1, Devonshire House,
One Mayfair Place,
London W1J 8AJ
United Kingdom